Sun Pharma Appoints Kirti Ganorkar as MD

In a major leadership transition, Sun Pharmaceutical Industries Ltd, India’s largest pharmaceutical company, has appointed Kirti Ganorkar as its Managing Director, effective September 1, 2025. The move marks the culmination of a carefully planned succession process, with founder Dilip Shanghvi transitioning to the role of Executive Chairman. While Ganorkar will oversee day-to-day business operations, Shanghvi will continue guiding the company’s long-term strategy and its specialty portfolio.

Why in News?

On June 14, 2025, Sun Pharma announced a significant leadership change aimed at reinforcing its long-term growth trajectory. Kirti Ganorkar’s elevation as MD and Dilip Shanghvi’s continued role as Executive Chairman underscore a strategic shift aligned with governance continuity, innovation, and global expansion. The announcement follows steady growth in Sun Pharma’s India business and reflects confidence in internal leadership development.

Background and Profile of Kirti Ganorkar

• Joined Sun Pharma in 1996.
• Educational Qualifications: Chemical Engineer and MBA.
• Since June 2019, led the India Business, driving consistent growth and market share expansion.

Previously led critical functions such as,

• Business Development, Marketing
• Mergers & Acquisitions
• IP & Litigation
• New Product Introductions and Project Management

Major Contributions

• Secured rights for Ilumya, a specialty product.
• Led entry into Japan and initiated groundwork for European expansion.
• Supported key generic product launches for the U.S. market.

Leadership Roles & Restructuring

• All business and functions will now report to Kirti Ganorkar.
• Appointment is subject to shareholder approval at the upcoming Annual General Meeting.
• Dilip Shanghvi will remain on board as Executive Chairman, offering strategic guidance and focusing on specialty portfolio growth.

Global Leadership Updates

• Abhay Gandhi, President & CEO – North America, to exit.
• Richard Ascroft appointed new CEO – North America, reporting to Aalok Shanghvi, Whole-time Director & COO.

Summary/Static	Details
Why in the news?	Sun Pharma Appoints Kirti Ganorkar as MD
New MD	Appointed Kirti Ganorkar
Ganorkar’s Tenure at Sun	Since 1996
Previous Role	Head of India Business (since 2019)
Areas of Experience	BD, M&A, Litigation, IP, Project Management, Japan/Europe/U.S. Expansions
Outgoing North America CEO	Abhay Gandhi